ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Fujifilm injects $800m into biologics production unit

Investment to double vaccine component output in US and expand UK facility

Fujifilm sees contract development and manufacturing of biologics as a key driver for growth.   © Reuters

TOKYO -- Fujifilm Holdings will spend 90 billion yen ($813 million) on biologics manufacturing unit Fujifilm Diosynth Biotechnologies, the company announced Tuesday, accelerating its push into a field that is experiencing surging demand amid the coronavirus pandemic.

Producing biologic treatments, which involve steps like making cell cultures and genetic manipulation, requires expensive equipment and advanced technology, leading more drugmakers to contract out their development and production to companies like Fujifilm Diosynth, a joint venture with trading house Mitsubishi Corp. The latest announcement brings Fujifilm's total investment in the sector to $5.5 billion.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more